Zepbound Outperforms Wegovy in Weight Loss Trial

By Rene Pretorius

December 6, 2024

The news release from Eli Lilly and Company, titled “Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial, highlights the critical comparison of Zepbound vs Wegovy in treating obesity. Zepbound has shown superior efficacy, making it a compelling option for managing weight in adults.

The SURMOUNT-5 trial involved adults living with obesity or overweight with at least one weight-related medical condition but without diabetes. Zepbound outperformed Wegovy on both the primary endpoint and five key secondary endpoints at 72 weeks. The trial demonstrated that Zepbound was superior to Wegovy in terms of weight loss. Participants using Zepbound achieved an average weight loss of 20.2%, compared to 13.7% for those taking Wegovy. In terms of absolute weight loss, those on Zepbound lost 50.3 lbs (22.8 kg), while participants on Wegovy lost 33.1 lbs (15.0 kg). A key secondary endpoint showed that 31.6% of people taking Zepbound achieved at least 25% body weight loss, compared to just 16.1% of those taking Wegovy.

Mechanism of Action – Zepbound vs Wegovy

Tirzepatide, the active ingredient in Zepbound, is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. In contrast, semaglutide is a mono GLP-1 receptor agonist.

Safety Profile

The overall safety profile of Zepbound in the SURMOUNT-5 trial was similar to previous studies. The most commonly reported adverse events were gastrointestinal-related and generally mild to moderate in severity.

Regulatory and Market Status

Tirzepatide is commercialized as Zepbound for adults with obesity or overweight and weight-related medical problems in some global markets outside the U.S. It received U.S. FDA approval on November 8, 2023, for this indication and is also marketed as Mounjaro for adults with type 2 diabetes.

Ongoing and Future Zepbound Studies

Ongoing studies of tirzepatide focus on its effects in four disease areas. These areas are chronic kidney disease (CKD), morbidity/mortality in obesity (MMO), moderate-to-severe obstructive sleep apnea (OSA), and heart failure with preserved ejection fraction (HFpEF). The data reinforces the efficacy and safety of Zepbound vs Wegovy in managing obesity. Zepbound is a significant treatment option for adults with obesity or those who are overweight and facing related medical challenges.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.